Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Prostate Cancer Clinical Trials

Provenge Registry for Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED)
Status Conditions Phase Study ID
Recruiting Advanced Prostate Cancer NA NCT01306890
Summary

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.


Investigator
Celestia Higano, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Subjects must be at least 18 years of age.
  • Subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment.
  • Subjects must understand and sign an informed consent form.
Last Updated
October 15, 2012
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.